Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharmacogenomics. 2012 Oct;13(13):1469-76. doi: 10.2217/pgs.12.122.

HLA polymorphisms influence the development of skin rash arising from treatment with EGF receptor inhibitors.

Author information

1
German Red Cross Blood Transfusion Service, Baden-Wuerttemberg-Hessen, Ulm, Germany.

Abstract

AIM:

Development of a skin rash under treatment with EGF receptor (EGFR) inhibitors (EGFRIs) has been linked to a favorable prognosis in some studies, suggesting a possible immunological role for EGFRIs in addition to direct antagonistic downstream effects. The present study aimed to investigate whether particular HLA polymorphisms found in cancer patients treated with EGFRIs are associated with the development of skin rash and overall survival rates.

PATIENTS & METHODS:

HLA typing was performed on 105 cancer patients and the development of skin rash was rated during the first 4 weeks of therapy with EGFRIs.

RESULTS:

A significantly lower incidence of skin rash was found in patients carrying the HLA-A*02:01 or HLA-A*03:01 alleles (hazard ratio: 0.277; 95% CI: 0.121-0.634; p = 0.002 and hazard ratio: 0.292; 95% CI: 0.113-0.752; p = 0.011, respectively); however, no association with worse survival was seen.

CONCLUSION:

The chances of developing a skin rash in patients treated with EGFRIs may be lower in patients that carry the HLA-A*02:01 or HLA-A*03:01 alleles, while the antitumor efficacy of EGFRIs does not seem to be significantly impaired in these patients.

PMID:
23057547
DOI:
10.2217/pgs.12.122
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center